Author

A. L. Cook

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Assay:CRISPR screen· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Pebay· 2 shared A. W. Hewitt· 2 shared B. Ptak· 2 shared B. Vogelstein· 2 shared C. Bettegowda· 2 shared K. M. Young· 2 shared K. W. Kinzler· 2 shared L. Dobbyn· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

A. Pebay

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape

A. L. Cook, S. Sur, L. Dobbyn, E. Watson, J. D. Cohen, B. Ptak, B. S. Lee, S. Paul, E. Hsiue, M. Popoli, B. Vogelstein, N. Papadopoulos, C. Bettegowda, K. Gabrielson, S. Zhou, , N. Wyhs

A SMG1 inhibitor disrupts nonsense-mediated decay, increasing expression of neoantigens from truncating mutations and enhancing immune targetable peptides on cancer cells.

bioRxiv · Dec 28, 2023Cancer Biology

Induced pluripotent stem cell derived pericytes respond to endogenous mediators of proliferation and contractility

N. E. King, J.-M. Courtney, L. S. Brown, A. J. Fortune, N. B. Blackburn, J. L. Fletcher, J. M. Cashion, J. Talbot, A. Pebay, A. W. Hewitt, G. P. Morris, K. M. Young, A. L. Cook, B. A. Sutherland

This study compares iPSC-derived pericytes to primary human brain vascular pericytes, showing they express pericyte markers and respond to growth factors and vasoactive mediators, though with gene expression differences.

bioRxiv · Sep 29, 2023Cell Biology

An Isogenic Cell Line Panel for Sequence-based Screening of Targeted Anti-cancer Drugs

A. L. Cook, N. Wyhs, S. B. Sur, B. Ptak, M. Popoli, L. Dobbyn, T. Papadopoulos, C. Bettegowda, N. Papadopoulos, B. Vogelstein, S. Zhou, K. W. Kinzler

The paper creates an isogenic cell line panel for drug screening, finding that most lines did not fully inactivate genes but a subset had biallelic disruptions, enabling drug response testing.

bioRxiv · Aug 6, 2021Cancer Biology

Comparison of CRISPR/Cas endonucleases for in vivo retinal gene editing.

F. Li, K. Wing, J.-H. Wang, C. D. Luu, J. A. Bender, J. Chen, Q. Wang, Q. Lu, M. T. N. T. Tran, K. M. Young, R. C. Wong, A. Pebay, A. L. Cook, S. S. Hung, G.-S. Liu, A. W. Hewitt

This study compares CRISPR/Cas endonucleases for in vivo retinal gene editing and finds SpCas9 delivered via AAV7m8 achieves the highest knockout efficacy.

bioRxiv · Jun 9, 2020Bioengineering